Anika Therapeutics
ANIK
126 hedge funds and large institutions have $483M invested in Anika Therapeutics in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 41 increasing their positions, 49 reducing their positions, and 14 closing their positions.
2.2% more ownership
Funds ownership: 91.21% → 93.4% (+2.2%)
4% less funds holding
Funds holding: 131 → 126 (-5)
14% less capital invested
Capital invested by funds: $560M → $483M (-$76.3M)
16% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 49
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Trigran Investments
Northbrook,
Illinois
|
+$6.63M |
| 2 |
Morgan Stanley
New York
|
+$5.04M |
| 3 |
Janus Henderson Group
London,
|
+$4.33M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$2.27M |
| 5 |
BlackRock
New York
|
+$1.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$5.63M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.28M |
| 3 |
JCIA
Jackson Creek Investment Advisors
Castle Rock,
Colorado
|
-$1.05M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$886K |
| 5 |
Renaissance Technologies
New York
|
-$825K |
ANIK Hedge Fund Activity: Q4 2021 in Review
126 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q4 2021, worth a combined $483M — down 14% from $560M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ANIK and 11 opened new positions — a net loss of 3 holders — while 49 trimmed existing stakes and 41 added.
The largest buyer was Trigran Investments, adding an estimated $6.63M. The largest seller was Assenagon Asset Management, cutting an estimated $5.63M.
- 126 institutional investors held Anika Therapeutics (ANIK) as of Q4 2021, down from 131 in Q3 2021.
- Funds reported $483M of Anika Therapeutics stock for Q4 2021, down 14% quarter-over-quarter.
- 11 funds opened new Anika Therapeutics positions in Q4 2021 and 14 closed out, a net change of -3 holders.
- The largest Anika Therapeutics buyer in Q4 2021 was Trigran Investments, an estimated $6.63M added.
- The largest Anika Therapeutics seller in Q4 2021 was Assenagon Asset Management, an estimated $5.63M sold.
Based on aggregated 13F filings for Q4 2021.